Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.

Necrotic tissue damage as a result of Duchenne muscular dystrophy

Similar stories

Innovation award for Paediatrics researcher to develop new treatments for childhood cancer

Awards & Appointments Haematology

Associate Professor Andi Roy leads one of the five research teams across the UK that have been awarded the 2021 Cancer Research UK-Children with Cancer UK Innovation Award. The awards, which provide a total of £4.3 million in scientific funding, will allow leading researchers in the field to delve into the biology of children’s and young people’s cancers, with the hope of finding new ways to prevent and treat these complex cancers.

Professor Matthew Snape named NIHR Senior Investigator

Awards & Appointments Vaccinology

Four academics supported by the NIHR Oxford Biomedical Research Centre have been awarded a prestigious national award, among them Matthew Snape from the Oxford Vaccine Group.

Enriching Engagement (Round 2) awardees announced

Awards & Appointments Neuromuscular Diseases Public Engagement

The awardees for the second round of the University of Oxford’s Enriching Engagement funding scheme have now been announced, including a project from Paediatrics.

Featured publication: Advances in oligonucleotide drug delivery

Neuromuscular Diseases Publication

Oligonucleotides - short DNA or RNA molecules - have great therapeutic application for a range of diseases. Yet, their potential has not been fully unleashed because of challenges linked to efficient delivery. Read more to find out about recent developments in oligonucleotide modifications, and the platforms that may be used to deliver them to target sites.

Typhoid vaccine project wins Vice-Chancellor award

Awards & Appointments Vaccinology

Congratulations to Professor Andrew Pollard who is the Winner of the Policy Engagement category in the Vice-Chancellor Innovation Awards 2020 for his work on Global policy on typhoid vaccines through research at Oxford!

Paediatrics project receives funding to assess novel coronavirus infection rates in children and teenagers across the UK

Awards & Appointments COVID-19 Vaccinology

A multi-site project, called ‘What’s the STORY?’ has received funding from UK Research and Innovation (UKRI) to assess novel coronavirus infection rates in children and teenagers across the UK. Given the importance of this study to the national Covid-19 response it has been deemed a priority study for the National Institute for Health Research’s (NIHR) Urgent Public Health Response.